GCA
HALO icon

Greenwood Capital Associates’s Halozyme HALO Stock Holding History

Greenwood Capital Associates’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
7,752
+32
+0.4% +$2.18K 0.06% 196
2026
Q1 		$499K Sell
7,720
-83
-1% -$5.85K 0.06% 206
2025
Q4 		$525K Buy
+7,803
New +$525K 0.06% 186

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Greenwood Capital Associates's HALO Position: Q2 2026 in Review

Greenwood Capital Associates increased its Halozyme (HALO) stake by 0.41% in Q2 2026, buying an estimated $2.18K and bringing the position to 7,752 shares worth $607K. The position accounts for 0.06% of the portfolio, ranked #196.

Greenwood Capital Associates first reported a position in HALO in Q4 2025 and has held it in 3 quarters since. 675 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Greenwood Capital Associates held 7,752 shares of Halozyme worth $607K as of Q2 2026.
  • Greenwood Capital Associates bought 32 Halozyme shares in Q2 2026, an estimated $2.18K.
  • Halozyme made up 0.06% of Greenwood Capital Associates's portfolio in Q2 2026, its #196 holding.
  • Greenwood Capital Associates first reported a position in Halozyme in Q4 2025 and has held it in 3 quarters since.
  • 675 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.